Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s): VYYRF

Healthcare Drug Manufacturers - Specialty & Generic

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.

TSXV:VM - Post by User

Voyageur Pharmaceuticals Ltd > Top 5 Global Partner

<< Previous

Bullboard Posts

Next >>

Comment by JrOGInvestoron Dec 20, 2024 11:47am

65 Views

Post# 36372303

RE:RE:Top 5 Global Partner

The list I'm looking at for top 5 are:

Bayer AG: 20 billion Euro company
GE Healthcare: 35 Billion US company
Bracco: N/A
Guerbet: 309 Million (not likely as one of the main goals was to gain inroads to US markets)
China also highly unlikely.

I'm betting it's one of the top 2 but it's just a guess. Either way it's a David and Goliath scenario where a multi billion dollar company is funding a 10 million dollar company.

Care to wager what happens when VM gets to 500million valuation?

<< Previous

Bullboard Posts

Next >>

Critical materials crisis: Diversifying away from China’s monopoly